Document Detail

Prevention of hepatitis B recurrence after liver transplantation.
MedLine Citation:
PMID:  16286888     Owner:  NLM     Status:  MEDLINE    
The reults of orthotopic liver transplantation (OLT) for hepatitis B virus (HBV) related liver disease are significantly influenced by the HBV recurrence rate. Complete eradication of hepatitis B is rarely possible after liver transplantation and hepatic and extrahepatic reservoirs are a continuous latent source of HBV recurrence. Therefore an adequate prophylaxis is mandatory. By introduction of long term passive immunoprophylaxis the recurrence rate could be markedly reduced and survival rates significantly improved. Due to the approval of antiviral drugs, especially lamivudine as the first approved antiviral agent against HBV, new prophylactic options, including combination prophylaxis, have been introduced. This modern antiviral managemant improved the outcome of hepatitis B patients after liver transplantation. The Results after OLT are nowadays reported to be as good or in a recent UNOS database report even better than in non-HBV patients. The type of recommended prophylaxis has undergone modifications within the last years and is still subject to changes due to the ongoing development of antiviral agents. In addition, due to high costs of hepatitis immunoglobulin alternatives such as prophylaxis with nucleos(t)ide analogues or vaccination are increasingly investigated. In the following, current strategies of reinfection prophylaxis and future perspectives are reviewed.
Daniel Seehofer; Thomas Berg
Related Documents :
21550008 - Characteristics of human immunodeficiency virus infections among the elderly in taiwan:...
21111238 - Abortive hiv infection mediates cd4 t cell depletion and inflammation in human lymphoid...
21406978 - The future of hiv testing.
21317598 - The bhives collaborative: organization and evaluation of a multisite demonstration of i...
12244588 - Hiv-1 rna and viral load.
17301558 - Investigating the utility of the hiv-1 bed capture enzyme immunoassay using cross-secti...
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Transplantation     Volume:  80     ISSN:  0041-1337     ISO Abbreviation:  Transplantation     Publication Date:  2005 Sep 
Date Detail:
Created Date:  2005-11-15     Completed Date:  2006-04-25     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0132144     Medline TA:  Transplantation     Country:  United States    
Other Details:
Languages:  eng     Pagination:  S120-4     Citation Subset:  IM    
Department of General, Visceral, and Transplantation Surgery, Charité Universitätsmedizin Berlin, Campus Virchow Klinikum, Berlin, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Antiviral Agents / therapeutic use
Hepatitis B / drug therapy,  prevention & control*,  surgery*
Immunization, Passive
Immunoglobulins / therapeutic use
Lamivudine / therapeutic use
Liver Transplantation / statistics & numerical data*
Reg. No./Substance:
0/Antiviral Agents; 0/Immunoglobulins; 0/hepatitis B hyperimmune globulin; 134678-17-4/Lamivudine

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Hepatocellular carcinoma: interventional bridging to liver transplantation.
Next Document:  Treatment of hepatitis C virus reinfection after liver transplantation.